Problems of selecting an anticoagulant for secondary stroke prevention in patients with atrial fibrillation
| Autor: | Gusev, V. V., Lvova, O. A., Shamalov, N. A. |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
DRUG EFFICACY CARDIOEMBOLIC STROKE SECONDARY PREVENTION DYSPHAGIA direct oral anticoagulants PROPHYLAXIS law.invention ATRIAL FIBRILLATION Randomized controlled trial law Internal medicine MOTOR DYSFUNCTION ischemic stroke Medicine COGNITIVE DEFECT Diseases of the circulatory (Cardiovascular) system atrial fibrillation cardiovascular diseases ARTICLE Stroke ANTICOAGULANT AGENT Secondary prevention Rivaroxaban business.industry Swallowing Disorders RIVAROXABAN HUMAN Atrial fibrillation SPEECH DISORDER medicine.disease TRANSIENT ISCHEMIC ATTACK RC666-701 Ischemic stroke ISCHEMIC STROKE Cardiology DIRECT ORAL ANTICOAGULANTS RANDOMIZED CONTROLLED TRIAL (TOPIC) Cardiology and Cardiovascular Medicine business Special problem secondary prevention medicine.drug |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 20, Iss 6 (2021) Cardiovasc. Ther. Prev. Cardiovascular Therapy and Prevention (Russian Federation) |
| ISSN: | 2619-0125 1728-8800 |
| Popis: | The article describes the urgent problem of ischemic stroke prevention in patients with atrial fibrillation. It is proved that ischemic stroke in combination with AF is the most severe in terms of developing stable motor and speech disorders and disability. The frail older patients, as well as patients with swallowing disorders and reduced medical adherence present a special problem from this point of view. The most famous clinical studies on secondary prevention of cardioembolic stroke are RE-LY, ROCKET-AF, and ARISTOTLE. Based on subanalyses of randomized controlled trials, direct oral anticoagulants demonstrated a favorable efficacy profile in patients with atrial fibrillation and stroke/ transient ischemic attack, but the level of knowledge on each of them remained different. A number of advantages of rivaroxaban for primary and secondary prevention of stroke in patients with atrial fibrillation, including the elderly and patients with cognitive impairments and swallowing disorders, have been demonstrated. © 2021 Vserossiiskoe Obshchestvo Kardiologov. All rights reserved. Relationships and Activities. This publication was supported by AO Bayer (PPM_RIVRU00581). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|